Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes
| العنوان: | Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes |
|---|---|
| المؤلفون: | Davide Imberti, Daniela Mastroiacovo |
| المصدر: | Internal and Emergency Medicine. 12:561-563 |
| بيانات النشر: | Springer Science and Business Media LLC, 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | medicine.medical_specialty, Pyridines, Pyridones, Administration, Oral, 030204 cardiovascular system & hematology, Dabigatran, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Rivaroxaban, Edoxaban, Internal Medicine, medicine, Humans, cardiovascular diseases, 030212 general & internal medicine, Intensive care medicine, Evidence-Based Medicine, Dose-Response Relationship, Drug, business.industry, Warfarin, Anticoagulants, Venous Thromboembolism, Reduced dose, Thiazoles, Regimen, chemistry, Emergency Medicine, Pyrazoles, Apixaban, business, Venous thromboembolism, medicine.drug |
| الوصف: | In the Hokusai-VTE trial, 733 patients were treated with the reduced dose edoxaban regimen, which maintained efficacy and safety compared with the 60 mg dose, and was safer than warfarin. The prophylactic doses of apixaban and rivaroxaban reduced the risk of recurrent venous thromboembolism (VTE) in the extended treatment trials. Dabigatran 110 mg was approved by the European Medicine Agency for VTE treatment. Further data from registries and real-world studies will help to clarify whether patients, with other specific characteristics, can benefit from the reduced dose of direct oral anticoagulants. |
| تدمد: | 1970-9366 1828-0447 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d1c5103f07c7c9096a21c1519d47972Test https://doi.org/10.1007/s11739-017-1688-7Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....3d1c5103f07c7c9096a21c1519d47972 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 19709366 18280447 |
|---|